Shares of Zydus Lifesciences surged by 4% after a major milestone: U.S. FDA approval for its novel drug, CUTX-101, to treat Menkes disease. This marks a critical breakthrough for both the company and patients battling the rare genetic condition.
A Breakthrough in Rare Disease Treatment
Menkes disease, an inherited disorder caused by a defect in copper absorption, primarily affects infants and results in severe developmental challenges. With no FDA-approved treatment available, the introduction of CUTX-101 (Copper Histidinate) could transform how this condition is managed.
The FDA’s acceptance of Zydus’ New Drug Application (NDA) is accompanied by a six-month priority review, setting a target decision date for June 30, 2025. This expedited review reflects the drug’s potential to address an unmet medical need.
If granted full approval, CUTX-101 would become the first therapy specifically designed to combat Menkes disease, offering families new hope where previously none existed.
Market Impact and Share Performance
The news immediately resonated with investors, pushing Zydus Lifesciences’ stock up by 3.7%, to ₹997.4, as of January 7, 2025. This marks a significant uptick from its previous close at ₹961.45.
Such market enthusiasm reflects both confidence in the company’s R&D pipeline and optimism about the drug’s commercial potential. A successful launch could bolster Zydus’ position as a global leader in pharmaceutical innovation.
Expanding Reach Through CVS Caremark Partnership
Adding to the momentum, Zydus has announced a strategic partnership with CVS Caremark, a division of CVS Health. This deal enables Zydus to include several key diabetes medications—Zituvio, Zituvimet, and Zituvimet XR—in the CVS Caremark template formulary.
The agreement, effective January 1, 2025, ensures wider access to these medications for U.S. patients. For Zydus, the deal signifies a deeper foothold in the competitive American pharmaceutical market.
A Leader in Innovation and Research
Zydus Lifesciences has consistently demonstrated its commitment to innovation, with a diverse portfolio that spans branded drugs, generics, biosimilars, and consumer healthcare products. Its focus on cutting-edge research has positioned it as a significant player in over 50 countries, driving advancements across various therapeutic areas.
The company’s latest achievements underscore its ability to deliver on both the scientific and commercial fronts, reinforcing its reputation as a trusted partner in global healthcare.
![gain Rise in Gold Rate in India After Falling Rs 21,200/24K; Will Gold Price Today Jump or Drop on 28 March? By Harshika Yadav Published: Saturday, March 28, 2026, 6:55 [IST] preference Add as a preferred source on Google Gold rates in India witnessed a modest recovery on March 27, 2026, after a sharp fall in the previous session, indicating a cautious stabilisation in the bullion market. The yellow metal had dropped by Rs 212 per gram (or Rs 21,200 per 100 grams) of 24 Karat (24K) earlier, but managed to regain some ground. Gold Price Updates as US-Iran Tensions Ease; Pakistan, Turkiye & Egypt Step Up Mediation Efforts The rise in yellow metal follows easing geopolitical concerns after US President Donald Trump signalled a delay in potential military action against Iran's energy infrastructure by 10 days, pushing the deadline to April 6. This development, along with ongoing diplomatic efforts, has helped support safe-haven demand. gold Rate Today Further adding to market sentiment, Pakistan's Foreign Minister Ishaq Dar confirmed that Islamabad is acting as an intermediary between the United States and Iran, relaying messages as part of efforts to de-escalate tensions. Countries like Türkiye and Egypt are also reportedly supporting the mediation process, offering some relief to global financial markets. Gold Rate in India: Check Latest 22K, 24K & 18K Gold Prices Per Gram 24 Karat Gold Rate Today in India In the 24 Karat segment, at the time of writing, the rate for 1 gram stood at Rs 14,471, rising by Rs 16 from Rs 14,455. For 8 grams, the price increased to Rs 1,15,768, up by Rs 128. The rate for 10 grams climbed to Rs 1,44,710, reflecting a gain of Rs 160, while 100 grams of 24 Karat gold were priced at Rs 14,47,100, marking an increase of Rs 1,600. 22 Karat Gold Rate Today in India The price of one gram of 22K stood at Rs 13,265, gaining Rs 15 from the previous session. For 8 grams, the rate rose to Rs 1,06,120, registering an increase of Rs 120. The cost of 10 grams advanced to Rs 1,32,650, up by Rs 150, while 100 grams were priced at Rs 13,26,500, reflecting a gain of Rs 1,500. 18 Karat Gold Rate Today in India The rate for one gram of 18K stood at Rs 10,853, up by Rs 12. For 8 grams, the price moved up to Rs 86,824, marking a gain of Rs 96. The rate for 10 grams climbed to Rs 1,08,530, increasing by Rs 120, while 100 grams were valued at Rs 10,85,300, reflecting an uptick of Rs 1,200. Latest MCX Gold Price In the domestic futures market, gold on the Multi Commodity Exchange (MCX) held firm above the Rs 1,44,500 level as per latest trading record, supported largely by the weakness in the Indian rupee, which continues to cushion local prices despite global volatility. Latest Spot Gold Rate The rebound in domestic gold rates comes alongside a recovery in international markets, where gold moved above the $4,400 per ounce mark. What Lies Ahead for Gold Prices? Check Gold Rate Prediction Jateen Trivedi, VP - Research Analyst (Commodity and Currency), LKP Securities, said, "Gold remained slightly positive, trading above $4,425 with highs near $4,475, supported by initial optimism around US-Iran talks. However, the sharp rise in crude continues to signal underlying market stress and inflation risks." From a technical perspective, he explained, "Technically, support is seen near Rs 1,42,000, while resistance is placed around Rs 1,46,500. Overall, gold is expected to remain volatile with limited upside unless clarity emerges on inflation and geopolitics."](https://keralanews247.com/wp-content/uploads/2026/03/rupee-and-dollar-scaled-120x86.png)
